Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24854089 | 0.92 | HDAC2 (0.34) | HSD11B1HDAC2HDAC1DRD2DRD3 | |
| SCHEMBL21472213 | 0.92 | HSD11B1 (0.34) | HSD11B1HDAC2HDAC1DRD2DRD3 | |
| SCHEMBL24854080 | 0.90 | HDAC2 (0.37) | HSD11B1HDAC2HDAC1DRD2DRD3 | |
| SCHEMBL24854220 | 0.90 | HDAC2 (0.31) | HSD11B1HDAC2HDAC1CNR2 | |
| SCHEMBL24854090 | 0.90 | CYP2D6 (0.36) | HSD11B1DRD2DRD3CYP1A2CYP2D6 | |
| SCHEMBL24854270 | 0.87 | HDAC2 (0.35) | HSD11B1HDAC2HDAC1DRD2DRD3 | |
| SCHEMBL24854099 | 0.85 | GRIN2D (0.32) | HSD11B1HDAC2HDAC1CYP1A2CNR2 | |
| SCHEMBL24854291 | 0.82 | CYP1A2 (0.36) | DRD2DRD3CYP1A2CYP2D6ALOX15 | |
| SCHEMBL24855098 | 0.81 | — | — | |
| SCHEMBL24856292 | 0.79 | KCNH2 (0.33) | CYP1A2CYP2D6ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | KRAS, NRAS, HRAS | HSD11B1 1515/4885HDAC2 1985/4885HDAC1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.